The Babak Lab – Exciting Progress in Melanoma Treatment: Personalized Vaccines Show Promise
Maria Babak, Head of Drug Discovery Lab at City University of Hong Kong, shared a post by on LinkedIn:
“Congratulations to Dr. Patrick Ott and Dr. Catherine Wu on their groundbreaking progress in melanoma treatment research! Explore the details of this research in The Babak Lab recent review.”
Quoting ‘s post:
“Exciting Progress in Melanoma Treatment: Personalized Vaccines Show Promise.
Melanoma, a formidable adversary, is now facing a promising challenger: personalized cancer vaccines are transforming the landscape of melanoma treatment. Unlike traditional vaccines, these personalized therapies target individual mutations present in a patient’s tumor cells, training the immune system to fight cancer effectively.
Dr. Patrick Ott and Dr. Catherine Wu, researchers at Dana-Farber, in collaboration with experts at the Broad Institute, pioneered the development of personalized cancer vaccines over a decade ago. Their groundbreaking work led to the creation of NeoVax, one of the first personalized cancer vaccines tested on patients, showing promising results.
Now, a phase 2 clinical trial of an mRNA-based personalized melanoma vaccine is open at Dana-Farber and nationwide for eligible patients with high-risk metastatic melanoma. Moreover, ongoing research aims to enhance the efficacy of melanoma vaccines by combining them with other immunotherapies.
Personalized vaccines hold great potential in not just melanoma but also in treating other cancers like renal cell carcinoma, glioblastoma multiforme, ovarian cancer, chronic leukemia, and lymphoma.
Join us in celebrating these advancements in cancer treatment and spreading awareness about personalized cancer vaccines! Together, we can make a difference in the fight against cancer.
If you want to learn more about the innovative work on personalized cancer vaccines at Dana-Farber please refer to the full article written by Beth Dougherty.
Image source: Dana-Farber Cancer Institute, Beth Dougherty, Melanoma Vaccine: Progress and Possibility.”
Source: Maria Babak/LinkedIn and
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023